Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK releases Lotronex rights to Prometheus

GSK releases Lotronex rights to Prometheus

9th November 2007

GlaxoSmithKline (GSK) has signed an agreement with Prometheus Laboratories which sees GSK release the rights to its Lotronex tablets in the US.

Prometheus, a speciality pharmaceutical company, will now market and sell Lotronex under an exclusive distribution agreement until the acquisition is completed, predicted to be in early 2008.

Lotronex is currently the only prescription drug approved by the US Food and Drug Administration for use in female patients with severe diarrhoea-predominant irritable bowel syndrome.

Prometheus will continue offering the treatment through the established Prescribing Programme for Lotronex (PPL) which only enables physicians who subscribe to the programme the ability to prescribe Lotronex.

Stan Hull, vice-president of US Pharmaceuticals at GSK, welcomed the acquisition of Lotronex rights to Prometheus.

“We believe that Prometheus is ideally positioned with their strong franchise and relationships with gastroenterologists to market Lotronex and to educate patients and physicians on its proper use,” he said.

The president and chief executive officer of Prometheus Joseph Limber expressed his delight with the decision, describing it as a “significant opportunity” for the company.

Last month, GSK and Synta Pharmaceuticals announced a joint development and commercialisation collaboration for STA-4783, indicated for use in treatment of metastatic melanoma.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.